COMMUNIQUÉS West-GlobeNewswire

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
30/09/2025
Watch the "What This Means" video here Featuring Company’s second-generation T-Cell Engager program and advantages over first-generation Company’s T-Cell Engager program has made improvements in manufacturability, [...]
24/7 Market News: Sportswear and Smart Textiles are likely Key Spider Silk Target Markets for Kraig Labs
30/09/2025
DENVER, Sept. 30, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and information, highlights the opportunity for recombinant spider [...]
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress
30/09/2025
The Company will present the reported topline results from its phase 3 SHIELD II trial at one of the world’s leading surgical conferences PETACH TIKVA, Israel, Sept. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: [...]
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer
30/09/2025
New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence of gastric cancer [...]
Coloplast A/S - Financial Calendar 2025-26
30/09/2025
Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: https://www.coloplast.com/investor-relations/events-calendar/ Kind regards, Investor Relations Coloplast A/S Tel [...]
The MUHC Foundation’s Inaugural Breakthrough Run Wins Big at the Montreal Marathon
30/09/2025
MONTREAL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The MUHC Foundation proudly hosted its inaugural Breakthrough Run at the Montreal Marathon, bringing together 22 teams and almost 200 dedicated runners, including health care [...]
La première édition de la Course vers la Percée de la Fondation du CUSM remporte un franc succès lors du Marathon de Montréal
30/09/2025
MONTRÉAL, 30 sept. 2025 (GLOBE NEWSWIRE) -- La Fondation du CUSM est fière d’avoir organisé sa première Course vers la Percée lors du Marathon de Montréal. Cet événement a réuni 22 équipes et près de 200 coureurs [...]
September 2025 Letter to Shareholders
30/09/2025
VANCOUVER, Washington, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As this pivotal year continues to take shape for CytoDyn Inc. (“CytoDyn” or the “Company”), I am pleased to share the progress we have made in [...]
Vivex Biologics Treats First Patient in its Restore Trial Evaluating VIA Disc NP™ for Patients with Degenerative Disc Disease
30/09/2025
MIAMI, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, a leader in developing and delivering innovative allografts, today announced that it has treated the first patient in its Restore U.S. clinical trial evaluating [...]
VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
30/09/2025
Partnership combines Secarna’s OligoCreator® platform with VERAXA’s technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseases ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, [...]
Catheter Precision, Inc. Announces Two New Patents to be Issued by USPTO
30/09/2025
FORT MILL, S.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac [...]
Prenetics Announces CEO Danny Yeung Keynote at Token 2049 Singapore
30/09/2025
- Keynote: “IM8: The World’s Fastest-Growing Supplement Brand Powering Our Bitcoin Treasury - Prenetics currently holds 246 BTC with a NAV of $28M - Prenetics has $63.5m of cash 1 CHARLOTTE, N.C., Sept. 30, 2025 (GLOBE [...]
Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA
30/09/2025
Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments OAK RIDGE, TN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), [...]
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
30/09/2025
VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is the first and only [...]
LifeMD Offers Ozempic® at $499 Per Month through Collaboration with Novo Nordisk
30/09/2025
Ozempic® is now available at this reduced price to eligible self-pay LifeMD patients NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced [...]
AssistRx Joins Second Annual Drug Channels Leadership Forum as Diamond Sponsor
30/09/2025
Invite-only event will address today’s most pressing healthcare system challenges ORLANDO, Fla., Sept. 30, 2025 (GLOBE NEWSWIRE) -- AssistRx , the advanced therapy initiation and patient solutions provider, today [...]
Umoja Biopharma Announces that UB-VV111 Receives FDA Fast Track Designation for Relapsed/Refractory B-Cell Malignancies
30/09/2025
SEATTLE, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, announced today that the U.S. Food and Drug [...]
Reunion Neuroscience Announces First Patient Dosed in REKINDLE Phase 2 Clinical Trial of RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses
30/09/2025
-- AjD Represents an Area of Significant Unmet Need; No U.S. Food and Drug Administration (FDA)-Approved Therapies Available -- -- Following Positive Topline Data in RECONNECT Phase 2 Trial, Expect to Initiate Phase 3 [...]
Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock
30/09/2025
BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today [...]

Pages